Axillar management after Neo-adjuvant chemotherapy ; Edinburgh Breast Unit 2016-17period
Association of Breast Surgery ePoster Library. Fernandez T. 05/13/19; 257055; P011
Teresa Fernandez
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P011
Topic: Axilla
Introduction:Recently
Neo adjuvant chemotherapy (NCAT) has gained therapeutic importance for downsizing
breast tumours but also for de-escalating axillary treatment. It is early days for
this approach as there is not yet proven evidence regarding oncological impact of
conservative management of the axilla following NCATAim:To analyse current practice regarding
axillary management post NCAT in a single unit during 2016-17Method:Retrospective observational study of breast cancer patients treated with NCAT during 2016-17 in a single Unit. The primary outcome
was to analyse our surgical management of the axilla post NCATResults:Out of 177 patients treated with NCAT,
130 had proved positive axilla (posA), 74%) at diagnosis whilst 47 (26%) were
negative. In the letter, 45 patients underwent an initial sentinel node biopsy
(SNB) post NCAT from whom 5 patients needed further Axillary Clearance (ANC). Average
nodes retrieved was 4.4 (1-11) using dual technique. In the posA group, 74 (56%) patients had an initial SNB from whom 20 (15%) required further ANC. The other 52 (40%), had just primary ANC. Therefore, the number of patients who avoided ANC in this group was 54 (42%). The distribucion of triple negatives and Her2 positives patients in our series was 49(28%) and 67(38%) respectively. Conclusions: Ninety-four (54%) patients out of the
total 177 were managed with SNB as a primary axillary surgical treatment post NACT,
whereas 54 (42%) avoided ANC. That result is encouraging to engage in more controlled
studies to support this conservative approach in selected patients.
Topic: Axilla
Introduction:Recently
Neo adjuvant chemotherapy (NCAT) has gained therapeutic importance for downsizing
breast tumours but also for de-escalating axillary treatment. It is early days for
this approach as there is not yet proven evidence regarding oncological impact of
conservative management of the axilla following NCATAim:To analyse current practice regarding
axillary management post NCAT in a single unit during 2016-17Method:Retrospective observational study of breast cancer patients treated with NCAT during 2016-17 in a single Unit. The primary outcome
was to analyse our surgical management of the axilla post NCATResults:Out of 177 patients treated with NCAT,
130 had proved positive axilla (posA), 74%) at diagnosis whilst 47 (26%) were
negative. In the letter, 45 patients underwent an initial sentinel node biopsy
(SNB) post NCAT from whom 5 patients needed further Axillary Clearance (ANC). Average
nodes retrieved was 4.4 (1-11) using dual technique. In the posA group, 74 (56%) patients had an initial SNB from whom 20 (15%) required further ANC. The other 52 (40%), had just primary ANC. Therefore, the number of patients who avoided ANC in this group was 54 (42%). The distribucion of triple negatives and Her2 positives patients in our series was 49(28%) and 67(38%) respectively. Conclusions: Ninety-four (54%) patients out of the
total 177 were managed with SNB as a primary axillary surgical treatment post NACT,
whereas 54 (42%) avoided ANC. That result is encouraging to engage in more controlled
studies to support this conservative approach in selected patients.
P011
Topic: Axilla
Introduction:Recently
Neo adjuvant chemotherapy (NCAT) has gained therapeutic importance for downsizing
breast tumours but also for de-escalating axillary treatment. It is early days for
this approach as there is not yet proven evidence regarding oncological impact of
conservative management of the axilla following NCATAim:To analyse current practice regarding
axillary management post NCAT in a single unit during 2016-17Method:Retrospective observational study of breast cancer patients treated with NCAT during 2016-17 in a single Unit. The primary outcome
was to analyse our surgical management of the axilla post NCATResults:Out of 177 patients treated with NCAT,
130 had proved positive axilla (posA), 74%) at diagnosis whilst 47 (26%) were
negative. In the letter, 45 patients underwent an initial sentinel node biopsy
(SNB) post NCAT from whom 5 patients needed further Axillary Clearance (ANC). Average
nodes retrieved was 4.4 (1-11) using dual technique. In the posA group, 74 (56%) patients had an initial SNB from whom 20 (15%) required further ANC. The other 52 (40%), had just primary ANC. Therefore, the number of patients who avoided ANC in this group was 54 (42%). The distribucion of triple negatives and Her2 positives patients in our series was 49(28%) and 67(38%) respectively. Conclusions: Ninety-four (54%) patients out of the
total 177 were managed with SNB as a primary axillary surgical treatment post NACT,
whereas 54 (42%) avoided ANC. That result is encouraging to engage in more controlled
studies to support this conservative approach in selected patients.
Topic: Axilla
Introduction:Recently
Neo adjuvant chemotherapy (NCAT) has gained therapeutic importance for downsizing
breast tumours but also for de-escalating axillary treatment. It is early days for
this approach as there is not yet proven evidence regarding oncological impact of
conservative management of the axilla following NCATAim:To analyse current practice regarding
axillary management post NCAT in a single unit during 2016-17Method:Retrospective observational study of breast cancer patients treated with NCAT during 2016-17 in a single Unit. The primary outcome
was to analyse our surgical management of the axilla post NCATResults:Out of 177 patients treated with NCAT,
130 had proved positive axilla (posA), 74%) at diagnosis whilst 47 (26%) were
negative. In the letter, 45 patients underwent an initial sentinel node biopsy
(SNB) post NCAT from whom 5 patients needed further Axillary Clearance (ANC). Average
nodes retrieved was 4.4 (1-11) using dual technique. In the posA group, 74 (56%) patients had an initial SNB from whom 20 (15%) required further ANC. The other 52 (40%), had just primary ANC. Therefore, the number of patients who avoided ANC in this group was 54 (42%). The distribucion of triple negatives and Her2 positives patients in our series was 49(28%) and 67(38%) respectively. Conclusions: Ninety-four (54%) patients out of the
total 177 were managed with SNB as a primary axillary surgical treatment post NACT,
whereas 54 (42%) avoided ANC. That result is encouraging to engage in more controlled
studies to support this conservative approach in selected patients.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}